RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
Phase of Trial: Phase IV
Latest Information Update: 10 Mar 2018
Price : $35 *
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms RECORA
- Sponsors Bayer
- 20 Jan 2018 Results of a final analysis presented at the 2018 Gastrointestinal Cancers Symposium
- 17 Jan 2018 According to a Bayer media release, data will be present at the American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancer Symposium 2018.
- 30 Aug 2017 Status changed from active, no longer recruiting to completed.